218 related articles for article (PubMed ID: 24855903)
1. Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.
Okosun J; Packham G; Fitzgibbon J
Expert Opin Investig Drugs; 2014 Oct; 23(10):1321-32. PubMed ID: 24855903
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic targeting in lymphoma.
Booth S; Collins G
Br J Haematol; 2021 Jan; 192(1):50-61. PubMed ID: 32609383
[TBL] [Abstract][Full Text] [Related]
3. Emerging epigenetic-modulating therapies in lymphoma.
Sermer D; Pasqualucci L; Wendel HG; Melnick A; Younes A
Nat Rev Clin Oncol; 2019 Aug; 16(8):494-507. PubMed ID: 30837715
[TBL] [Abstract][Full Text] [Related]
4. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).
Braun T; Gardin C
Expert Opin Investig Drugs; 2017 Jul; 26(7):803-811. PubMed ID: 28541716
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic target discovery and drug development in cancer stem cells for leukemia and lymphoma: from bench to the clinic.
Laranjeira AB; Yang SX
Expert Opin Drug Discov; 2016 Nov; 11(11):1071-1080. PubMed ID: 27626707
[TBL] [Abstract][Full Text] [Related]
6. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
Genta S; Pirosa MC; Stathis A
Curr Oncol Rep; 2019 Feb; 21(2):13. PubMed ID: 30715616
[TBL] [Abstract][Full Text] [Related]
7. Investigational drugs for T-cell lymphoma.
Ghez D; Danu A; Ribrag V
Expert Opin Investig Drugs; 2016; 25(2):171-81. PubMed ID: 26576861
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic drugs against cancer: an evolving landscape.
Di Costanzo A; Del Gaudio N; Migliaccio A; Altucci L
Arch Toxicol; 2014 Sep; 88(9):1651-68. PubMed ID: 25085708
[TBL] [Abstract][Full Text] [Related]
9. Investigational new drugs for brain cancer.
Staedtke V; Bai RY; Laterra J
Expert Opin Investig Drugs; 2016 Aug; 25(8):937-56. PubMed ID: 27170161
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics and oncology.
Mummaneni P; Shord SS
Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
[TBL] [Abstract][Full Text] [Related]
11. Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.
Kühnl A; Cunningham D; Chau I
Cancer Treat Rev; 2017 Sep; 59():132-137. PubMed ID: 28822237
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
Chaidos A; Caputo V; Karadimitris A
Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
[TBL] [Abstract][Full Text] [Related]
13. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
14. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
15. Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.
Gelato KA; Adler D; Ocker M; Haendler B
Expert Opin Ther Targets; 2016 Jul; 20(7):783-99. PubMed ID: 26799480
[TBL] [Abstract][Full Text] [Related]
16. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy of acute myeloid leukemia.
Carneiro BA; Altman JK; Kaplan JB; Ossenkoppele G; Swords R; Platanias LC; Giles FJ
Expert Rev Anticancer Ther; 2015 Apr; 15(4):399-413. PubMed ID: 25623136
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia.
Fulda S
Br J Haematol; 2009 May; 145(4):441-54. PubMed ID: 19298593
[TBL] [Abstract][Full Text] [Related]
19. The development of targeted new agents to improve the outcome for children with leukemia.
Bautista F; Van der Lugt J; Kearns PR; Mussai FJ; Zwaan CM; Moreno L
Expert Opin Drug Discov; 2016 Nov; 11(11):1111-1122. PubMed ID: 27670965
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of P-glycoprotein expression in haematological malignancies.
Nooter K; Sonneveld P
Leuk Res; 1994 Apr; 18(4):233-43. PubMed ID: 7909572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
